Nevro Corp

+0.28 (+0.78%)

Nevro Announces FDA Submission For Hf10® Therapy In Patients With Painful Diabetic Neuropathy

Published: 12/28/2020 21:21 GMT
Nevro Corp (NVRO) - Nevro Announces FDA Submission for Hf10® Therapy in Patients With Painful Diabetic Neuropathy.
Nevro Corp -submission Would Position Co to Achieve Approval, Initiate U.S. Launch Activities for Senza System and Hf10 Therapy in Second Half of 2021.